Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Manresa – page 4

62 clinical trials in Manresa, Spain. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Manresa at a glance
62
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

62 trials in Manresa

Open in trial search

Hormone receptor positive breast cancer+1

Not recruiting

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Neratinib
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Fianlimab, Cemiplimab, and Chemotherapy in Adults with Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Neoplasm

Not recruiting

Study of EOS884448, Dostarlimab, and Inupadenant for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:iTeos Belgium

Colorectal cancer metastatic+14

Not recruiting

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Non-small cell lung cancer+1

Not recruiting

Study of Chemotherapy and Nivolumab Before and After Surgery for Patients with Non-Small Cell Lung Cancer in the Upper Lung Area

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Fundacion GECP

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Olema Pharmaceuticals Inc.

Corneal dystrophy

Not recruiting

Study on the Safety and Effectiveness of Ripasudil Eye Drops for Patients with Fuchs Endothelial Corneal Dystrophy After Descemetorhexis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Ripasudil
  • Sponsor:Kowa Research Institute Inc.

Prostate cancer metastatic

Not recruiting

Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Pfizer Inc.

Bladder cancer

Not recruiting

Study on Atezolizumab with Radiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Grupo Espanol De Oncologia Genitourinaria-Socug

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Manresa

What the registry says about research in the country

01 Oncology - Breast Cancer Research

Extensive clinical trials focusing on triple-negative breast cancer and HER2-positive breast cancer treatments, evaluating innovative therapies including atezolizumab, abemaciclib, and elacestrant.

  • Early-stage breast cancer treatments
  • Hormone receptor-positive therapy
  • Neoadjuvant chemotherapy approaches

Studies aim to improve survival rates and treatment outcomes through personalized therapeutic approaches.

02 Urological Oncology

Groundbreaking research in urothelial cancer and prostate cancer treatments, investigating novel combinations of immunotherapy and targeted therapies.

  • Metastatic castration-resistant prostate cancer
  • Bladder cancer interventions
  • Advanced urothelial carcinoma

Focus on improving progression-free survival through innovative treatment combinations.

03 Respiratory Medicine

Advanced research in severe asthma and lung cancer treatments, exploring new therapeutic approaches including immunotherapy combinations.

  • Non-small cell lung cancer therapy
  • Eosinophilic asthma management
  • Targeted respiratory interventions

Innovative approaches combining surgery, chemotherapy, and immunotherapy for optimal patient outcomes.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.